Anti-ALIX antibody [EPR23653-32] (Ab275377)
AIP1, ALIX, KIAA1375, PDCD6IP, Programmed cell death 6-interacting protein, PDCD6-interacting protein, ALG-2-interacting protein 1, ALG-2-interacting protein X, Hp95
详细信息
背景信息
What is this antibody validated in? Anti-ALIX antibody [EPR23653-32] (ab275377) is a rabbit recombinant monoclonal antibody and is validated for use in Western Blot (WB), Flow Cytometry (Intra), Flow Cytometry (Flow Cyt), Immunoprecipitation (IP), Immunocytochemistry/immunofluorescence (ICC/IF) in Human, Mouse, Rat samples. What is the molecular weight of ALIX? Anti-ALIX [EPR23653-32] (ab275377) specifically detects a band for ALIX (UniProt: Q8WUM4) at a molecular weight of 96kDa. Trusted by the scientific community Anti-ALIX [EPR23653-32] (ab275377) was first used in a scientific publication in 2020 and has been cited over 20 times in peer-reviewed journals. Specificity confirmed The specificity of Anti-ALIX antibody [EPR23653-32] (ab275377) has been confirmed by Western blot testing in PDCD6IP Knockout HEK293T cells. Other related products We have a range of other formats of antibody clone [EPR23653-32] also available for your convenience: ab275377, Carrier free - ab275387, Carrier free - ab277681 Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents. What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies. Trial sizes available! Test your antibody or perform pre-screening before committing to a larger quantity. Sold in 20µl. Discover our selection of trial-size antibodies.
文献引用 (133)
Dual metabolic-inflammation modulation in MicroRNA@neutrophil-derived microvesicles achieve robust osteoarthritis therapy.
MicroRNA@中性粒细胞衍生的微囊泡中的双重代谢-炎症调节可实现强效的骨关节炎治疗。
Transcatheter Intra-Arterial Delivery of a Platelet-Derived Extracellular Vesicle-Enriched Preparation for Attenuating Skeletal Muscle Ischaemia-Reperfusion Injury in a Rodent Forelimb Model.
经导管动脉内递送富含血小板衍生细胞外囊泡的制剂以减轻啮齿动物前肢模型中的骨骼肌缺血再灌注损伤。
Engineered CAR-T-Derived Exosomes Co-Delivering miR-145 and Cytotoxic Proteins for Targeted Solid Tumour Therapy.
工程化 CAR-T 衍生外泌体共递送 miR-145 和细胞毒性蛋白用于靶向实体瘤治疗。
Type II Alveolar Epithelial Cells Promote Sepsis-Induced Immunosuppression in Alveolar Macrophages via Exosomal lncRNA Rmrp Release.
II 型肺泡上皮细胞通过外泌体 lncRNA Rmrp 释放促进脓毒症诱导的肺泡巨噬细胞免疫抑制。
MiR-1290 in natural killer cell derived extracellular vesicles: a pathogenic mediator of lupus nephritis and therapeutic target for th17 regulation.
自然杀伤细胞衍生的细胞外囊泡中的 miR-1290:狼疮性肾炎的致病介质和 th17 调控的治疗靶点。
Programmable iPSC-derived CAR-NK vesicles remodel the immune microenvironment and eradicate tumors
可编程的iPSC衍生CAR-NK囊泡重塑免疫微环境并根除肿瘤
Neuronal PPP2R5C in plasma is a potential biomarker for early diagnosis of Alzheimer's disease.
血浆中的神经元 PPP2R5C 是一种潜在的阿尔茨海默病早期诊断生物标志物。
An autonomous siRNA delivery system targeting NLRP3: implications in Parkinson's disease.
靶向 NLRP3 的自主 siRNA 递送系统:对帕金森病的影响。
MYO1C is a urinary extracellular vesicle biomarker and mediator of podocyte injury in diabetic nephropathy.
MYO1C 是尿液细胞外囊泡生物标志物,也是糖尿病肾病中足细胞损伤的介质。
Naoxintong capsule decreases circulating exosomes of miR-382-5p to protect LPS-induced vascular endothelial cell injury by targeting STC1 in vitro.
钠心通胶囊通过靶向 STC1 在体外降低循环外泌体中 miR-382-5p 的含量,从而保护 LPS 诱导的血管内皮细胞损伤。
- 1
- 2
- 3
- 4
- 5
- 6
- 14